APA

Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., Yamamoto N., Hida T., Maemondo M., Nakagawa K., Nagase S., Okamoto I., Yamanaka T., Tajima K., Harada R., Fukuoka M. & Yamamoto N. (20150127). Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. : The Lancet. Oncology.

Chicago

Seto Takashi, Kato Terufumi, Nishio Makoto, Goto Koichi, Atagi Shinji, Hosomi Yukio, Yamamoto Noboru, Hida Toyoaki, Maemondo Makoto, Nakagawa Kazuhiko, Nagase Seisuke, Okamoto Isamu, Yamanaka Takeharu, Tajima Kosei, Harada Ryosuke, Fukuoka Masahiro and Yamamoto Nobuyuki. 20150127. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. : The Lancet. Oncology.

Harvard

Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., Yamamoto N., Hida T., Maemondo M., Nakagawa K., Nagase S., Okamoto I., Yamanaka T., Tajima K., Harada R., Fukuoka M. and Yamamoto N. (20150127). Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. : The Lancet. Oncology.

MLA

Seto Takashi, Kato Terufumi, Nishio Makoto, Goto Koichi, Atagi Shinji, Hosomi Yukio, Yamamoto Noboru, Hida Toyoaki, Maemondo Makoto, Nakagawa Kazuhiko, Nagase Seisuke, Okamoto Isamu, Yamanaka Takeharu, Tajima Kosei, Harada Ryosuke, Fukuoka Masahiro and Yamamoto Nobuyuki. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. : The Lancet. Oncology. 20150127.